Edition:
India

Vaxart Inc (VXRT.OQ)

VXRT.OQ on NASDAQ Stock Exchange Capital Market

2.90USD
15 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.90
Open
$2.95
Day's High
$2.95
Day's Low
$2.95
Volume
4
Avg. Vol
11,641
52-wk High
$11.88
52-wk Low
$2.77

Summary

Name Age Since Current Position

Wouter Latour

2018 President, Chief Executive Officer, Director

John Harland

62 2018 Chief Financial Officer

Sean Tucker

2018 Chief Scientific Officer

David Taylor

2018 Chief Medical Officer

Michael Finney

2018 Director

Jan Leschly

78 2018 Director

Richard Markham

66 2018 Director

Geoffrey Cox

72 2012 Independent Director

John Richard

59 2013 Independent Director

Anne VanLent

68 2013 Independent Director

Biographies

Name Description

Wouter Latour

Dr. Wouter W. Latour serves as President, Chief Executive Officer, Director of the company. From January 2005 to May 2009, Dr. Latour was Chief Executive Officer and a member of the board of directors of Trinity Biosystems, Inc., a biopharmaceutical company. Prior to these roles, Dr. Latour held numerous executive positions at various pharmaceutical and biotechnology companies. Dr. Latour received an M.D. from the University of Amsterdam and his M.B.A. from Stanford University.

John Harland

Mr. John M. Harland serves as Chief Financial Officer of the company. From June 2011 to March 2014, Mr. Harland served as Chief Financial Officer and Secretary of Wafergen Biosystems, Inc., a life sciences company focused on molecular biomarkers. From 2008 to 2010, Mr. Harland was Vice President of Finance and Administration and Assistant Secretary at Trinity Biosystems, Inc., a company focusing on oral delivery biopharmaceuticals. Mr. Harland began his career at Arthur Young & Company and is a certified public accountant (inactive) and holds FCA credentials. Mr. Harland received an M.A. in business studies and natural sciences from Cambridge University and his M.B.A. in taxation and finance at Golden Gate University.

Sean Tucker

Dr. Sean N. Tucker serves as Chief Scientific Officer of the company. From March 2004 to February 2010, Dr. Tucker served as our Vice President of Research and Director of Immunology. Prior to this, Dr. Tucker numerous scientific and engineering roles at various biotechnology companies. Dr. Tucker received a B.S. in chemical engineering from the University of Washington, an M.S. in chemical engineering from the University of California, Berkeley and a Ph.D. in immunology from the University of Washington.

David Taylor

Dr. David Taylor is Chief Medical Officer of the Company. Prior to joining Vaxart, Dr. Taylor served as a senior medical officer of the drug and vaccine development global programs at PATH, where he developed clinical trial designs and executed studies for seasonal and universal flu vaccines and enteric vaccines. Earlier, he was senior medical director of vaccines at Takeda Vaccines, developing clinical trial plans for norovirus and dengue vaccines. Previously, Dr. Taylor served as chief medical officer at VaxInnate Corporation, where he focused on the development of recombinant vaccines for influenza and other infectious diseases, and chief medical officer and vice president of medical and safety at Salix Pharmaceuticals, where he developed Rifaximin (Xifaxan) for the treatment of traveller's diarrhea and headed medical affairs and pharmacovigilance. Dr. Taylor earned his MSc. in Medical Parasitology from the London School of Hygiene and Tropical Medicine, M.D. from Harvard Medical School, D.M.S. from Dartmouth Medical School and B.S. in Biology from Kenyon College.

Michael Finney

Dr. Michael J. Finney serves as Director of the company. Since October 2004, Dr. Finney has served as the Managing Director of Finney Capital, a venture capital firm. Since 1986, Dr. Finney has served as a founder, director and/or investor in various life science companies. Currently, he sits on six private boards. From 2009 to 2011, Dr. Finney served as chief executive officer of the Company. Dr. Finney received an A.B. in biochemical sciences from Harvard University and a Ph.D. in biology (genetics) from the Massachusetts Institute of Technology.

Jan Leschly

Mr. Jan Leschly serves as Director of the company. Mr. Leschly founded Care Capital, LLC, a venture capital firm, in 2001 and has served as its Chairman and Managing Partner since 2001. Since 2005, Mr. Leschly has served as an Adjunct Professor at Copenhagen’s School of Business. Since 2000, Mr. Leschly has served on the board of directors of A.P. Moller-Maersk Group. Mr. Leschly received a B.S. in business administration from the Copenhagen School of Economics and Business Administration and an M.S. in pharmacy from the Copenhagen College of Pharmacy.

Richard Markham

Mr. Richard J. Markham serves as Director of the company. Since November 2004, Mr. Markham has been a partner at Care Capital, LLC, a venture capital firm. From May 2002 to August 2004, he was the Vice Chairman of the Management Board and Chief Operating Officer of Aventis SA, a pharmaceutical company. From December 1999 to May 2002, he was the Chief Executive Officer of Aventis Pharma AG, a pharmaceutical company. Previously he was the Chief Executive Officer of Hoechst Marion Roussel Inc., a pharmaceutical company, and the President and Chief Operating Officer of Marion Merrell Dow, Inc., a pharmaceutical company, and a member of its board of directors. From 1973 to 1993, Mr. Markham was associated with Merck & Co., a pharmaceutical company, culminating in his position as President and Chief Operating Officer. Since 2007, Mr. Markham has served as a member of the board of directors of NephroGenex, Inc. and as its board chairman since October 2013. Since 2008, he has also served on the board of directors of CoLuid Pharmaceuticals, Inc. Previously, Mr. Markham served on the board of directors of Acura Pharmaceuticals, Inc. from 2006 to 2013, on the board of directors of Anacor Pharmaceuticals, Inc. from 2005 to 2012 and Commerce Bank of Kansas City from 2003 to 2004. Mr. Markham received a B.S. in pharmacy and pharmaceutical sciences from Purdue University.

Geoffrey Cox

Dr. Geoffrey F. Cox, Ph.D. is Independent Director of the Company. He is currently the interim Chief Executive Officer of QLT Inc., an ophthalmology company based in Vancouver, BC, (since October 2014) and a Director (since 2012). Dr. Cox has extensive pharmaceutical and biotechnology experience holding a broad range of senior management and board positions with private and public companies. Dr. Cox remains the Principal of Beacon Street Advisors LLC (since 2013) which provides corporate, operational and organizational strategic advice and interim management support to life sciences companies, but is working full time for QLT at this time. Previously, he was a partner with Red Sky Partners LLC, a life sciences consulting firm (from 2011 to 2013). He also served as a Director of Gallus Biopharmaceuticals LLC (2011 – 2014), a biologics contract manufacturing and development company, and currently serves as a Director of Lakewood-Amedex LLC (since 2013), a company developing novel antibiotics and RNA silencing technology. Dr. Cox was Chairman, President and CEO of GTC Biotherapeutics Inc. (now rEVO Biologics) (2001 to 2010), a company focused on the development of recombinant therapeutic proteins, including proteins for the treatment of rare diseases, using transgenic animal production technology. Prior to 2001, Dr. Cox is a past Chairman and current member of the Board of the Massachusetts Biotechnology Council. He previously served on the Board of Biotechnology Industries Association and as a member of its Health Governing and Emerging Companies Sections. Dr. Cox received a B.Sc. (Hons) in biochemistry from the University of Birmingham, UK and PhD in biochemistry from the University of East Anglia,

John Richard

Mr. John P. Richard is Independent Director of the Company. He is co-founder and Head of Corporate Development for Mereo BioPharma Group plc, a publicly-traded biotechnology company. Mr. Richard is also an Operating Partner and non-executive director of Phase4 Partners, a venture capital firm based in London, UK, and had been a Partner of Georgia Venture Partners, LLC, a venture capital firm that focuses on the biotechnology industry from 2005 to 2015. He has also served as a senior business adviser to a number of biotechnology companies as well as a consultant to numerous portfolio companies of Georgia Venture Partners and Phase4 Ventures. Previously, he held senior executive business development positions at SEQUUS Pharmaceuticals, Inc., VIVUS, Inc. and Genome Therapeutics Corporation. Since August 2015, Mr. Richard serves a director of Catalyst Biosciences, Inc. a publicly-traded biotechnology company that merged with Targacept, Inc. Mr. Richard served as a director of Targacept from November 2002 to August 2015, the time of the merger, and was its Chairman from January 2014 through the completion of the merger. He currently serves as a Director of QUE Oncology and as Senior Business Advisor to Albireo AB. Mr. Richard has also been a director of QUE Oncology, Inc. a privately-held biotechnology company, since 2013. Mr. Richard received a M.B.A. from Harvard Business School and a B.S. from Stanford University. Mr. Richard’s extensive executive, strategic, financial and business development experience within the biotechnology industry, and having led the business development function at several companies resulting in numerous pharmaceutical alliances, led to the conclusion that he should serve on the Company’s Board of Directors.

Anne VanLent

Ms. Anne M. VanLent is Independent Director of the Company. She is currently President of AMV Advisors, which provides corporate strategy and financial consulting services to emerging growth life sciences companies. From May 2002 to April 2008, Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly-traded pharmaceutical company. From July 1997 to October 2001, she was the Executive Vice President – Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. Ms. VanLent currently serves as a director and chairs the audit committees of Aegerion Pharmaceuticals, Inc., Ocera Therapeutics, Inc., and Applied Genetics Technologies Corporation (AGTC), all of which are publicly-traded companies. During the past five years, Ms. VanLent also served as a director of Onconova Therapeutics, Inc. where she also served as Audit Chair, and as a director of Integra Life Sciences Corporation, a publicly-traded biotechnology company, until May 2012. Ms. VanLent received a B.A. degree in Physics from Mount Holyoke College. Ms. VanLent’s extensive leadership and finance experience, and her extensive experience serving as a board member, audit committee member and audit committee chair of numerous public companies in the life sciences industry, led to the conclusion that she should serve on the Company’s Board of Directors.